THE POTENTIAL IMPACT OF SWITCH TO SECOND GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE WHO HAD NO OPTIMAL RESPONSE TO 3 MONTHS OF INITIAL IMATINIB THERAPY: PS1183
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI